PROSTATE CANCER EQUITY CROWDFUNDING CAMPAIGN
We are launching an equity crowdfunding campaign for our revolutionary prostate cancer diagnostic test.
Join us to help bring this technology to a worldwide life sciences market and share in our success as a Cambridge Oncometix shareholder.
If you are a UK taxpayer, an investment in Cambridge Oncometrix can provide you with tax relief of up to 50% of the value of the investment.
Shares and tax relief opportunities are limited and will be allocated on a first-come, first-served basis.
Sign up now to avoid missing out.
INTERESTED IN FINDING OUT MORE ABOUT THE CAMBRIDGE ONCOMETRIX CROWDFUNDING CAMPAIGN?
Fill in your details below for more information, updates on the diagnostic test development and our upcoming crowdfunding campaign.
1 in 8 men will develop prostate cancer once in their lifetime. Current diagnostic procedures are inaccurate and invasive. We have discovered and patented biomarkers in semen samples that help to select menfor aprostate biopsy more accurately than the PSA test.
Our product has secured £1.5 million pounds worth of funding including £1.1 million pounds from the NHS to trial, refine and implement it in the UK health system.
We currently conduct a multi-centreclinical study in the UK led by the University College London and aim to launch the test next year.
Sign up for our Crowdfunding Newsletter to learn more.